Serveur d'exploration SRAS

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Coronaviruses and their therapy

Identifieur interne : 000539 ( PascalFrancis/Curation ); précédent : 000538; suivant : 000540

Coronaviruses and their therapy

Auteurs : Bart L. Haagmans [Pays-Bas] ; Albert D. M. E. Osterhaus [Pays-Bas]

Source :

RBID : Pascal:06-0491674

Descripteurs français

English descriptors

Abstract

Coronaviruses may cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses hampered development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) has prompted the discovery of such drugs. Subsequent studies in animal models demonstrated the efficacy of SARS-CoV specific monoclonal antibodies, pegylated-interferon-a and siRNAs against SARS-CoV. Furthermore, several antivirals shown to be effective against other viruses were tested in vitro. Because of availability and shown efficacy, the use of interferons may be considered should SARS-CoV or a related coronavirus (re)-emerge. The more recent design of wide-spectrum inhibitors targeting the coronavirus main proteases may lead to the discovery of new antivirals against multiple coronavirus induced diseases.
pA  
A01 01  1    @0 0166-3542
A02 01      @0 ARSRDR
A03   1    @0 Antivir. res.
A05       @2 71
A06       @2 2-3
A08 01  1  ENG  @1 Coronaviruses and their therapy
A11 01  1    @1 HAAGMANS (Bart L.)
A11 02  1    @1 OSTERHAUS (Albert D. M. E.)
A14 01      @1 Department of Virology, Erasmus Medical Center Rotterdam, Dr. Molewaterplein 50 @2 3015 GE Rotterdam @3 NLD @Z 1 aut. @Z 2 aut.
A20       @1 397-403
A21       @1 2006
A23 01      @0 ENG
A43 01      @1 INIST @2 18839 @5 354000142317820390
A44       @0 0000 @1 © 2006 INIST-CNRS. All rights reserved.
A45       @0 2 p.
A47 01  1    @0 06-0491674
A60       @1 P
A61       @0 A
A64 01  1    @0 Antiviral research
A66 01      @0 NLD
C01 01    ENG  @0 Coronaviruses may cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses hampered development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) has prompted the discovery of such drugs. Subsequent studies in animal models demonstrated the efficacy of SARS-CoV specific monoclonal antibodies, pegylated-interferon-a and siRNAs against SARS-CoV. Furthermore, several antivirals shown to be effective against other viruses were tested in vitro. Because of availability and shown efficacy, the use of interferons may be considered should SARS-CoV or a related coronavirus (re)-emerge. The more recent design of wide-spectrum inhibitors targeting the coronavirus main proteases may lead to the discovery of new antivirals against multiple coronavirus induced diseases.
C02 01  X    @0 002B02S05
C03 01  X  FRE  @0 Traitement @5 01
C03 01  X  ENG  @0 Treatment @5 01
C03 01  X  SPA  @0 Tratamiento @5 01
C03 02  X  FRE  @0 Article synthèse @5 02
C03 02  X  ENG  @0 Review @5 02
C03 02  X  SPA  @0 Artículo síntesis @5 02
C03 03  X  FRE  @0 Syndrome respiratoire aigu sévère @2 NM @5 03
C03 03  X  ENG  @0 Severe acute respiratory syndrome @2 NM @5 03
C03 03  X  SPA  @0 Síndrome respiratorio agudo severo @2 NM @5 03
C03 04  X  FRE  @0 Antiviral @5 04
C03 04  X  ENG  @0 Antiviral @5 04
C03 04  X  SPA  @0 Antiviral @5 04
C03 05  X  FRE  @0 Coronavirus @2 NW @5 05
C03 05  X  ENG  @0 Coronavirus @2 NW @5 05
C03 05  X  SPA  @0 Coronavirus @2 NW @5 05
C03 06  X  FRE  @0 Inhibiteur d'entrée @4 INC @5 86
C03 07  X  FRE  @0 inhibiteur de réplication @4 INC @5 87
C03 08  X  FRE  @0 Inhibiteur de fusion @4 CD @5 96
C03 08  X  ENG  @0 Fusion inhibitor @4 CD @5 96
C03 08  X  SPA  @0 Inhibidor fusión @4 CD @5 96
C07 01  X  FRE  @0 Virose
C07 01  X  ENG  @0 Viral disease
C07 01  X  SPA  @0 Virosis
C07 02  X  FRE  @0 Infection
C07 02  X  ENG  @0 Infection
C07 02  X  SPA  @0 Infección
C07 03  X  FRE  @0 Coronaviridae @2 NW
C07 03  X  ENG  @0 Coronaviridae @2 NW
C07 03  X  SPA  @0 Coronaviridae @2 NW
C07 04  X  FRE  @0 Nidovirales @2 NW
C07 04  X  ENG  @0 Nidovirales @2 NW
C07 04  X  SPA  @0 Nidovirales @2 NW
C07 05  X  FRE  @0 Virus @2 NW
C07 05  X  ENG  @0 Virus @2 NW
C07 05  X  SPA  @0 Virus @2 NW
C07 06  X  FRE  @0 Appareil respiratoire pathologie @5 37
C07 06  X  ENG  @0 Respiratory disease @5 37
C07 06  X  SPA  @0 Aparato respiratorio patología @5 37
C07 07  X  FRE  @0 Poumon pathologie @5 38
C07 07  X  ENG  @0 Lung disease @5 38
C07 07  X  SPA  @0 Pulmón patología @5 38
N21       @1 317

Links toward previous steps (curation, corpus...)


Links to Exploration step

Pascal:06-0491674

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Coronaviruses and their therapy</title>
<author>
<name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L." last="Haagmans">Bart L. Haagmans</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Virology, Erasmus Medical Center Rotterdam, Dr. Molewaterplein 50</s1>
<s2>3015 GE Rotterdam</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author>
<name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Virology, Erasmus Medical Center Rotterdam, Dr. Molewaterplein 50</s1>
<s2>3015 GE Rotterdam</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">06-0491674</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0491674 INIST</idno>
<idno type="RBID">Pascal:06-0491674</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000451</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000539</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Coronaviruses and their therapy</title>
<author>
<name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L." last="Haagmans">Bart L. Haagmans</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Virology, Erasmus Medical Center Rotterdam, Dr. Molewaterplein 50</s1>
<s2>3015 GE Rotterdam</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
<author>
<name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name>
<affiliation wicri:level="1">
<inist:fA14 i1="01">
<s1>Department of Virology, Erasmus Medical Center Rotterdam, Dr. Molewaterplein 50</s1>
<s2>3015 GE Rotterdam</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
<imprint>
<date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Antiviral research</title>
<title level="j" type="abbreviated">Antivir. res.</title>
<idno type="ISSN">0166-3542</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Antiviral</term>
<term>Coronavirus</term>
<term>Fusion inhibitor</term>
<term>Review</term>
<term>Severe acute respiratory syndrome</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Traitement</term>
<term>Article synthèse</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Antiviral</term>
<term>Coronavirus</term>
<term>Inhibiteur d'entrée</term>
<term>inhibiteur de réplication</term>
<term>Inhibiteur de fusion</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Coronaviruses may cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses hampered development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) has prompted the discovery of such drugs. Subsequent studies in animal models demonstrated the efficacy of SARS-CoV specific monoclonal antibodies, pegylated-interferon-a and siRNAs against SARS-CoV. Furthermore, several antivirals shown to be effective against other viruses were tested in vitro. Because of availability and shown efficacy, the use of interferons may be considered should SARS-CoV or a related coronavirus (re)-emerge. The more recent design of wide-spectrum inhibitors targeting the coronavirus main proteases may lead to the discovery of new antivirals against multiple coronavirus induced diseases.</div>
</front>
</TEI>
<inist>
<standard h6="B">
<pA>
<fA01 i1="01" i2="1">
<s0>0166-3542</s0>
</fA01>
<fA02 i1="01">
<s0>ARSRDR</s0>
</fA02>
<fA03 i2="1">
<s0>Antivir. res.</s0>
</fA03>
<fA05>
<s2>71</s2>
</fA05>
<fA06>
<s2>2-3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG">
<s1>Coronaviruses and their therapy</s1>
</fA08>
<fA11 i1="01" i2="1">
<s1>HAAGMANS (Bart L.)</s1>
</fA11>
<fA11 i1="02" i2="1">
<s1>OSTERHAUS (Albert D. M. E.)</s1>
</fA11>
<fA14 i1="01">
<s1>Department of Virology, Erasmus Medical Center Rotterdam, Dr. Molewaterplein 50</s1>
<s2>3015 GE Rotterdam</s2>
<s3>NLD</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA20>
<s1>397-403</s1>
</fA20>
<fA21>
<s1>2006</s1>
</fA21>
<fA23 i1="01">
<s0>ENG</s0>
</fA23>
<fA43 i1="01">
<s1>INIST</s1>
<s2>18839</s2>
<s5>354000142317820390</s5>
</fA43>
<fA44>
<s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45>
<s0>2 p.</s0>
</fA45>
<fA47 i1="01" i2="1">
<s0>06-0491674</s0>
</fA47>
<fA60>
<s1>P</s1>
</fA60>
<fA61>
<s0>A</s0>
</fA61>
<fA64 i1="01" i2="1">
<s0>Antiviral research</s0>
</fA64>
<fA66 i1="01">
<s0>NLD</s0>
</fA66>
<fC01 i1="01" l="ENG">
<s0>Coronaviruses may cause respiratory, enteric and central nervous system diseases in many species, including humans. Until recently, the relatively low burden of disease in humans caused by few of these viruses hampered development of coronavirus specific therapeutics. However, the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) has prompted the discovery of such drugs. Subsequent studies in animal models demonstrated the efficacy of SARS-CoV specific monoclonal antibodies, pegylated-interferon-a and siRNAs against SARS-CoV. Furthermore, several antivirals shown to be effective against other viruses were tested in vitro. Because of availability and shown efficacy, the use of interferons may be considered should SARS-CoV or a related coronavirus (re)-emerge. The more recent design of wide-spectrum inhibitors targeting the coronavirus main proteases may lead to the discovery of new antivirals against multiple coronavirus induced diseases.</s0>
</fC01>
<fC02 i1="01" i2="X">
<s0>002B02S05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE">
<s0>Traitement</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG">
<s0>Treatment</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA">
<s0>Tratamiento</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE">
<s0>Article synthèse</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG">
<s0>Review</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA">
<s0>Artículo síntesis</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE">
<s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG">
<s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA">
<s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE">
<s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG">
<s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA">
<s0>Antiviral</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE">
<s0>Coronavirus</s0>
<s2>NW</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG">
<s0>Coronavirus</s0>
<s2>NW</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA">
<s0>Coronavirus</s0>
<s2>NW</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE">
<s0>Inhibiteur d'entrée</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE">
<s0>inhibiteur de réplication</s0>
<s4>INC</s4>
<s5>87</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE">
<s0>Inhibiteur de fusion</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG">
<s0>Fusion inhibitor</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA">
<s0>Inhibidor fusión</s0>
<s4>CD</s4>
<s5>96</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE">
<s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG">
<s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA">
<s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE">
<s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG">
<s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA">
<s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE">
<s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG">
<s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA">
<s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE">
<s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG">
<s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA">
<s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE">
<s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG">
<s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA">
<s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE">
<s0>Appareil respiratoire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG">
<s0>Respiratory disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA">
<s0>Aparato respiratorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE">
<s0>Poumon pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG">
<s0>Lung disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA">
<s0>Pulmón patología</s0>
<s5>38</s5>
</fC07>
<fN21>
<s1>317</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000539 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000539 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:06-0491674
   |texte=   Coronaviruses and their therapy
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021